Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Spectrum Health

Neither a doctor nor a teaching hospital

Research payments

$1,822,207

267 payments

Through program year 2025, Spectrum Health is reported as receiving $1,822,207 in research payments, across 267 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $449,237 78
2024 Research $230,933 24
2023 Research $303,793 20
2022 Research $201,156 31
2021 Research $528,787 36
2020 Research $42,122 4
2019 Research $66,180 74

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $451,609 18 payments
  2. E.R. Squibb & Sons, L.L.C. $353,573 6 payments
  3. Medtronic, Inc. $328,808 49 payments
  4. Abbott Laboratories $271,240 68 payments
  5. Shape Memory Medical Inc. $92,252 14 payments
  6. Lexicon Pharmaceuticals, Inc. $73,448 12 payments
  7. Eisai Inc. $58,774 5 payments
  8. Alexion Pharmaceuticals, Inc. $56,848 6 payments
  9. Rapid Medical LTD $31,958 3 payments
  10. AbbVie, Inc. $26,902 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 $431,774 12 payments
  2. A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy (VALOR-HCM) $275,150 2 payments
  3. Spyral Affirm $239,581 16 payments
  4. NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure $81,913 8 payments
  5. AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion $78,002 11 payments
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis $56,848 6 payments
  7. SONATA-HCM / Sotagliflozin / LX4211 $46,087 7 payments
  8. A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP (EMBARK-HFpEF) $45,409 2 payments
  9. CATALYST IDE Study $38,378 8 payments
  10. A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy $32,474 4 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $6,900 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record